This article is more than 5 years old. Information may no longer be current.

Allergan submits application to FDA for Oculeve intranasal tear neurostimulator

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan has filed a de novo application to the FDA for the Oculeve intranasal tear neurostimulator, according to a company press release.

The hand-held stimulator can temporarily increase tear production in patients with dry eye disease due to decreased tear production.

“The Oculeve intranasal tear neurostimulator is an exciting potential option for patients suffering from dry eye disease, and we are pleased to have filed the de novo application with FDA that will allow patients to gain access to this novel medical device,” David Nicholson, chief research and development officer at Allergan, said in the release.

Allergan recently announced that the device met its effectiveness endpoints in two pivotal trials.